Is A a good stock to buy? We came across a bullish thesis on Agilent Technologies, Inc. on Quality At A Fair Price’s Substack. In this article, we will summarize the bulls’ thesis on A. Agilent ...

(NYSE: A) will release financial results for the second quarter of fiscal year 2026 after the stock market closes on Wednesday, May 27. The company will host a conference call to discuss the results ...

Let's talk about the popular Agilent Technologies, Inc. . The company's shares received a lot of attention from a substantial ...

Over the past six months, Agilent’s stock price fell to $118.28. Shareholders have lost 16.7% of their capital, which is disappointing considering the S&P 500 has climbed by 5.4%. This may have ...

Agilent Technologies has agreed to acquire Resolution Bioscience for up to $695 million, the companies said Tuesday, in a deal intended to expand the buyer’s precision medicine offerings by ...

Agilent stands out as a focused, well-managed leader in life science instruments, with strong financials and resilience amid global trade headwinds. The Ignite transformation program enhances supply ...

Agilent has boosted its contract development and manufacturing organisation (CDMO) capacity with a $925 million deal to buy Biovectra, a Canadian provider of fill-and-finish services and active ...

The Agilent 5800/5900 ICPOES’ new ‘Smart Tools’, free-form optical components, along with Agilent’s patented background correction and interference removal techniques, will make it much easier to meet ...

Expands Agilent’s pathology portfolio through addition of highly complementary antibody, reagent and instrument business with annual double-digit revenue and profit growth since 2021 Expected to be ...

Agilent has agreed to acquire Biovectra for $925 million, the companies said today, in a deal intended to expand the buyer’s contract development and manufacturing (CDMO) portfolio to the production ...

Agilent is a wonderful business with a strong competitive moat, decent growth, and excellent profitability. The company benefits from customer "stickiness" and growth in the biopharmaceutical sector.

With the acquisition of BioVectra and a growing focus on advanced therapeutics, the company is positioning itself differently ...